CNBC Pro

History shows this 4th quarter rally is likely almost over

More In Pro Insight

Three pharmaceutical stocks were last week's top performers — and analysts gave one 40% upside
CNBC ProThree pharmaceutical stocks were last week's top performers — and analysts gave one 40% upside
Fund manager names two global retailers that are about to 'dominate'
CNBC ProFund manager names two global retailers that are about to 'dominate'
Goldman Sachs upgrades this global tech giant, saying the stock could rise up to 90%
CNBC ProGoldman Sachs upgrades this global tech giant, saying the stock could rise up to 90%